Please use this identifier to cite or link to this item: http://dx.doi.org/10.25673/116547
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGriewing, Sebastian-
dc.contributor.authorKnitza, Johannes-
dc.contributor.authorBoekhoff, Jelena-
dc.contributor.authorHillen, Christoph-
dc.contributor.authorLechner, Fabian-
dc.contributor.authorWagner, Uwe-
dc.contributor.authorWallwiener, Markus-
dc.contributor.authorKuhn, Sebastian-
dc.date.accessioned2024-07-08T06:23:23Z-
dc.date.available2024-07-08T06:23:23Z-
dc.date.issued2024-
dc.identifier.urihttps://opendata.uni-halle.de//handle/1981185920/118504-
dc.identifier.urihttp://dx.doi.org/10.25673/116547-
dc.description.abstractPurpose: This study investigated the concordance of five different publicly available Large Language Models (LLM) with the recommendations of a multidisciplinary tumor board regarding treatment recommendations for complex breast cancer patient profiles. Methods: Five LLM, including three versions of ChatGPT (version 4 and 3.5, with data access until September 3021 and January 2022), Llama2, and Bard were prompted to produce treatment recommendations for 20 complex breast cancer patient profiles. LLM recommendations were compared to the recommendations of a multidisciplinary tumor board (gold standard), including surgical, endocrine and systemic treatment, radiotherapy, and genetic testing therapy options. Results: GPT4 demonstrated the highest concordance (70.6%) for invasive breast cancer patient profiles, followed by GPT3.5 September 2021 (58.8%), GPT3.5 January 2022 (41.2%), Llama2 (35.3%) and Bard (23.5%). Including precancerous lesions of ductal carcinoma in situ, the identical ranking was reached with lower overall concordance for each LLM (GPT4 60.0%, GPT3.5 September 2021 50.0%, GPT3.5 January 2022 35.0%, Llama2 30.0%, Bard 20.0%). GPT4 achieved full concordance (100%) for radiotherapy. Lowest alignment was reached in recommending genetic testing, demonstrating a varying concordance (55.0% for GPT3.5 January 2022, Llama2 and Bard up to 85.0% for GPT4). Conclusion: This early feasibility study is the first to compare different LLM in breast cancer care with regard to changes in accuracy over time, i.e., with access to more data or through technological upgrades. Methodological advancement, i.e., the optimization of prompting techniques, and technological development, i.e., enabling data input control and secure data processing, are necessary in the preparation of large-scale and multicenter studies to provide evidence on their safe and reliable clinical application. At present, safe and evidenced use of LLM in clinical breast cancer care is not yet feasible.eng
dc.language.isoeng-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subject.ddc610-
dc.titleEvolution of publicly available large language models for complex decision-making in breast cancer careeng
dc.typeArticle-
local.versionTypepublishedVersion-
local.bibliographicCitation.journaltitleArchives of gynecology and obstetrics-
local.bibliographicCitation.volume310-
local.bibliographicCitation.pagestart537-
local.bibliographicCitation.pageend550-
local.bibliographicCitation.publishernameSpringer-
local.bibliographicCitation.publisherplaceBerlin-
local.bibliographicCitation.doi10.1007/s00404-024-07565-4-
local.openaccesstrue-
dc.identifier.ppn1894412117-
cbs.publication.displayform2024-
local.bibliographicCitation.year2024-
cbs.sru.importDate2024-07-08T06:22:46Z-
local.bibliographicCitationEnthalten in Archives of gynecology and obstetrics - Berlin : Springer, 1870-
local.accessrights.dnbfree-
Appears in Collections:Open Access Publikationen der MLU

Files in This Item:
File Description SizeFormat 
s00404-024-07565-4.pdf958.82 kBAdobe PDFThumbnail
View/Open